中国医药涉1.39亿诉讼一审判决，结果尚不确定

Core Viewpoint - China National Pharmaceutical Group Corporation is involved in a legal dispute regarding performance compensation contracts, with a lawsuit filed against Tibet Tiansheng Taifeng Pharmaceutical Co., Ltd. and Xu Panfeng, amounting to 139.4041 million yuan [1] Group 1: Legal Proceedings - The lawsuit was initiated in October 2024, and Tibet Tiansheng has filed a counterclaim during the court proceedings [1] - The Beijing Second Intermediate People's Court has issued a first-instance judgment requiring Tibet Tiansheng to pay performance compensation and interest to China National Pharmaceutical, while Xu Panfeng is jointly liable for the payment [1] - China National Pharmaceutical is also required to pay equity transfer fees and interest to Tibet Tiansheng [1] Group 2: Current Status - As of the announcement date, the first-instance judgment has not taken effect, and the possibility of an appeal and the final outcome remain uncertain [1] - The company will disclose further developments in accordance with regulations and reminds investors to be aware of the associated risks [1]